絞り込み

17438

広告

Mutational spectrum of acquired resistance to reversible versus irreversible EGFR tyrosine kinase inhibitors.

著者 Wagener-Ryczek S , Heydt C , Süptitz J , Michels S , Falk M , Alidousty C , Fassunke J , Ihle MA , Tiemann M , Heukamp L , Wolf J , Büttner R , Merkelbach-Bruse S
BMC Cancer.2020 May 12 ; 20(1):408.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (6view , 0users)

Full Text Sources

Miscellaneous

Research Materials

Over the past years, EGFR tyrosine kinase inhibitors (TKI) revolutionized treatment response. 1st-generation (reversible) EGFR TKI and later the 2nd -generation irreversible EGFR TKI Afatinib were aimed to improve treatment response. Nevertheless, diverse resistance mechanisms develop within the first year of therapy. Here, we evaluate the prevalence of acquired resistance mechanisms towards reversible and irreversible EGFR TKI.
PMID: 32397977 [PubMed - in process]
印刷用ページを開く Endnote用テキストダウンロード